Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

134 Results

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Updated

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Updated

Mar 2025

Guidelines and Advice

The Treatment of Lymphedema Related to Breast Cancer

Status: Archived
ID: 13-1

Aug 2003

Guidelines and Advice

Radiotherapy Fractionation for the Palliation of Uncomplicated Painful Bone Metastases

Status: Archived
ID: 13-2

Mar 2003

Guidelines and Advice

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Status: Current
ID: MOTAC-7

Updated

Jan 2025

Guidelines and Advice

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Status: Current

Updated

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program recommendations for cervical screening and colposcopy with human papillomavirus testing in Ontario

Updated

Mar 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Updated

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program: Guidance for Vaginal Vault Testing

Status: Current

Updated

Mar 2025

Guidelines and Advice

Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

Status: Current
ID: GL 17-10 v2
Version: 2

Updated

Mar 2025

Guidelines and Advice

Use of 5-HT3 Receptor Antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Status: Archived
ID: 12-3

Jan 2003

Guidelines and Advice

Hyperfractionated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Archived
ID: 5-6b

Jan 2003

Pages